Intellia Therapeutics Inc.

In News

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates - Intellia Therapeutics

Intellia Therapeutics - Nov 06, 2025

Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA) - Seeking Alpha

Seeking Alpha - Dec 02, 2025

Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat

MarketBeat - Dec 14, 2025

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - Yahoo Finance

Yahoo Finance - Nov 25, 2025

For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat - statnews.com

statnews.com - Oct 27, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire - Dec 05, 2025

Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory - Finviz

Finviz - Dec 04, 2025

Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies - CGTLive®

CGTLive® - Nov 09, 2025

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics

Intellia Therapeutics - Nov 10, 2025

623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc - MarketBeat

MarketBeat - Dec 14, 2025

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Yahoo Finance - Nov 06, 2025

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics

Intellia Therapeutics - Oct 27, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment